Aaron Wealth Advisors LLC Has $480,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Aaron Wealth Advisors LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 41.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,576 shares of the biopharmaceutical company’s stock after buying an additional 4,878 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Pfizer were worth $480,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Olistico Wealth LLC bought a new stake in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at approximately $29,000. Quarry LP bought a new stake in Pfizer during the 2nd quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC raised its holdings in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer in the second quarter valued at approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.1 %

PFE stock opened at $29.23 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The business’s fifty day moving average price is $29.07 and its two-hundred day moving average price is $28.44. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The stock has a market capitalization of $165.64 billion, a price-to-earnings ratio of -63.54, a PEG ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -365.21%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday. They set a “market perform” rating and a $32.00 target price for the company. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $33.91.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.